Apixaban Dose Selection in Kidney Failure: Reconciling Pharmacokinetics and Clinical Outcomes

To compare pharmacokinetic, clinical outcomes, and regulatory evidence for apixaban 5 mg versus 2.5 mg twice daily in kidney failure on hemodialysis with atrial fibrillation (AF), and propose a framework for individualized dose selection.

PubMed, EMBASE, and the Cochrane Library were searched from inception through June 2026 using terms including apixaban, kidney failure, hemodialysis, AF, pharmacokinetics (PK), and dosing.

PK studies, observational cohorts, randomized controlled trials (RCTs), network meta-analyses, regulatory documents, and guidelines evaluating apixaban dosing in kidney failure and AF were included.

Five PK studies (n ≈ 112) showed 2.5 mg twice daily produced steady-state levels comparable to 5 mg in normal renal function, while 5 mg produced approximately 3-fold supratherapeutic exposure. Of the 3 observational studies, 2 linked 5 mg to lower mortality; 1 found 63% higher bleeding with 5 mg and no difference in stroke/systemic embolism (subdistribution hazard ratio (SHR) 1.01; 95% CI, 0.59-1.73) or death (hazard ratio [HR] 1.03; 95% CI, 0.77-1.38). Two RCTs (RENAL-AF and AXADIA-AFNET 8) were terminated early and remain underpowered. Confounding by indication, competing risk of death, and misapplication of dose-reduction criteria likely explain this paradox.

This review provides the first systematic reconciliation of this paradox, identifying confounding by indication, competing risk of death, and structural flaws in the US Food and Drug Administration (FDA) dose-reduction criteria as likely explanations for the discordance. It gives clinical pharmacists a framework for appraising the evidence rather than defaulting to the FDA label or PK data alone, and proposes a decision algorithm for individualized dosing, derived from expert opinion, PK, and observational data and requiring prospective validation.

The optimal apixaban dose in kidney failure remains unresolved. Neither dose has been shown to reduce stroke versus no anticoagulation in this population. Dose selection should be individualized to patient-specific factors.